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ABSTRACT
Smarcal1 is a SWI/SNF-family protein with an ATPase
domain involved in DNA-annealing activities and a
binding site for the RPA single-strand-DNA-binding
protein. Although the role played by Smarcal1 in the
maintenance of replication forks has been estab-
lished, it remains unknown whether Smarcal1 con-
tributes to genomic DNA maintenance outside of the
S phase. We disrupted the SMARCAL1 gene in both
the chicken DT40 and the human TK6 B cell lines. The
resulting SMARCAL1−/− clones exhibited sensitivity
to chemotherapeutic topoisomerase 2 inhibitors, just
as nonhomologous end-joining (NHEJ) null-deficient
cells do. SMARCAL1−/− cells also exhibited an in-
crease in radiosensitivity in the G1 phase. More-
over, the loss of Smarcal1 in NHEJ null-deficient
cells does not further increase their radiosensitivity.
These results demonstrate that Smarcal1 is required
for efficient NHEJ-mediated DSB repair. Both inac-
tivation of the ATPase domain and deletion of the
RPA-binding site cause the same phenotype as does
null-mutation of Smarcal1, suggesting that Smarcal1
enhances NHEJ, presumably by interacting with RPA
at unwound single-strand sequences and then facil-
itating annealing at DSB ends. SMARCAL1−/−cells
showed a poor accumulation of Ku70/DNA-PKcs and
XRCC4 at DNA-damage sites. We propose that Smar-
cal1 maintains the duplex status of DSBs to ensure
proper recruitment of NHEJ factors to DSB sites.
INTRODUCTION
Smarcal1 (a SWI/SNF-related, matrix associated, actin-
dependent regulator of chromatin a-like 1) is a SWI/SNF
family protein that carries an ATPase domain and the
binding site for replication protein A (RPA), the single-
strand-DNA-binding protein (1,2). Smarcal1 is an ATP-
driven annealing helicase that catalyzes the formation of
double-strand DNA from complementary single-strand
DNA strands associated with RPA. Thus, Smarcal1 could
counteract unwinding by DNA helicases at DSB sites. The
annealing activity is stimulated by substrate DNA contain-
ing both single-strand and double-strand regions, such as a
chicken foot structure (3). Mutations in the SMARCAL1
gene cause a rare autosomal recessive disease, Schimke
immuno-osseous dysplasia (SIOD), which is characterized
by short stature, kidney disease and a severely compromised
immune system (4–7). Phenotypic analysis of Smarcal1-
depleted cells suggests that Smarcal1 stabilizes replication
forks when cells are exposed to aphidicolin, hydroxyurea
and camptothecin (a topoisomerase 1 poison) (1,2,8–10).
The two major double-strand-break (DSB) repair path-
ways, homologous recombination (HR) and nonhomolo-
gous end-joining (NHEJ) (11–13) significantly contribute
to cellular tolerance to anti-malignant therapies. First, both
pathways contribute to cellular tolerance to radiotherapy,
HR in the S to G2 phases and NHEJ throughout the cell
cycle. Second, HR plays the dominant role in repairing
DSBs generated during DNA replication by chemother-
apeutic agents such as camptothecin and poly[ADP ri-
bose]polymerase inhibitor (olaparib). These chemother-
apeutic agents cause the accumulation of single-strand
breaks, which are converted by DNA replication to DSBs
called one-end breaks. These DSBs are repaired by HR
but not by NHEJ (14–16). Third, NHEJ plays the domi-
nant role in repairing DSBs caused by chemotherapeutic
topoisomerase 2 inhibitors such as ICRF193 and etopo-
side (15,17). Measuring the sensitivity of gene-disrupted
cells to various anti-malignant therapies allows us to de-
fine the role of the gene in HR, NHEJ or both. In addition
to the above, the capability of canonical NHEJ is evaluated
*To whom correspondence should be addressed. Tel: +81 75 753 4410; Fax: +81 75 753 4419; Email: hiroysasa@rg.med.kyoto-u.ac.jp
C© The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
 Nucleic Acids Research Advance Access published June 18, 2015
 at Library of Research Reactor Institute, K
yoto U






2 Nucleic Acids Research, 2015
by examining the V(D)J recombination of Immunoglobulin
(Ig) V genes, which requires a collaboration between NHEJ
and V(D)J recombinase encoded by the recombination-
activating-genes 1 and 2 (Rag1/Rag2) (18–20).
Canonical NHEJ is initiated by associating aKu70/Ku80
heterodimer with DSB sites. Ku70/Ku80 associates prefer-
entially with duplex DNA ends, rather than with DSBs car-
rying single-strand tails generated by exonucleases or DNA
helicases (21–24). Ku70/Ku80 forms a complex with DNA-
dependent-protein-kinase catalytic subunit (DNA-PKcs),
leading to the activation of DNA-PKcs at DSB sites (25–
27). DNA-PKcs phosphorylates a number of substrates, in-
cluding itself (28–31). Ligase4 (Lig4) completes DSB re-
pair in collaboration with the essential co-factors, XLF and
XRCC4, which form clamp-like structures along duplex
DNA (32–35). If canonical NHEJ does not perform DSB
repair, non-canonical end-joining such as microhomology-
mediated alternative end-joining (MMEJ) repairs DSBs,
though less efficiently than canonical NHEJ, causing dele-
tion near the DSB sites (36,37).
We disrupted the SMARCAL1 gene in the chicken DT40
and human B lymphoblastoid TK6 cell lines (38,39). The
resulting SMARCAL1−/− clones exhibited sensitivity to
camptothecin, suggesting that Smarcal1 plays a role in
DNA replication, as indicated previously (9,10). Remark-
ably, Smarcal1 is also required for efficient NHEJ in human
as well as in chicken cells. This conclusion is in agreement
with the fact that SIOD patients exhibit reduced V(D)J re-
combination products in peripheral lymphocytes as well as
increased chromosomal breakage (40,41). We propose that
the decreased efficiency of NHEJ in V(D)J recombination
as well as the compromised maintenance of replication fork




All the clones used in this study are summarized in Table 1.
Cell culture
DT40 and TK6 cells were cultured in the same manner as
described previously (39,42).
Generation of SMARCAL1−/− DT40 cells
SMARCAL1 gene disruption constructs were generated
from genomic polymerase chain reaction (PCR) prod-
ucts combined with histidinol dehydrogenase (hisD) and
puromycin-resistance (puroR) marker genes. GenomicDNA
from wild-type cells was amplified using the F1 and R1
primers for the 5′-arm and the F2 and R2 primers for
the 3′-arm. The amplified 3′-arm PCR product was sub-
cloned into pCR2.1-TOPO vector (Invitrogen, US). The
5′-arm PCR product harboring the SacI and BamHI sites
at the 5′- and 3′-ends, respectively, was cloned into the
SacI and BamHI sites of the pCR2.1-TOPO vector car-
rying the 3′-arm. The BamHI fragment containing either
the hisD or puroR gene was cloned into the BamHI site
between the 3′-arm and the 5′-arm in the pCR2.1-TOPO
vector. To generate SMARCAL1−/− cells, the SMARCAL1
gene-disruption constructs carrying hisD and puroR were
linearized, using the NotI restriction enzyme, and sequen-
tially transfected by electroporation (Bio-Rad, US). A 0.5
kb probe was generated by PCR of genomic DNA using
primers F3 and R3 for Southern blot analysis. The genomic
DNA of the candidate clones was digested with SmaI and
XhoI for Southern blot analysis. The gene disruption was
confirmed by RT-PCR, using primers F4 and R4. When
generating SMARCAL1+/− clones from wild-type cells the
targeting efficiency was 20% (4/20), while that of generating
SMARCAL1−/− cells from SMARCAL1+/− cells was 1.4%
(1/71). All primers used here are shown in Supplemental
Table S1.
Generation of SMARCAL1Δ30/− and
KU70−/−/SMARCAL1Δ30/− DT40 cells
The intact allele of the SMARCAL1+/− cell was targeted
for deleting the first 30 amino acids, which domain is re-
sponsible for RPA binding (10). To generate the Δ30 con-
struct, the 5′-arm was amplified from genomic DNA us-
ing the NotI-tagged F5 and the BamHI-tagged R5, and
the 3′-arm was amplified using the BamHI-tagged F6,
which was designed from 90 bases downstream of start
codon ATG in exon1, and the SalI-tagged R6. In the Zero
Blunt TOPO vector (Invitrogen, US), the left and right
arms were cloned at the site of NotI-BamHI and BamHI-
SalI, respectively. The selection-marker gene, puromycin
resistance (puroR) flanked by loxP sequences, was then
inserted into the BamHI site between the left and right
arms. The resulting Δ30-puroR construct was transfected
into the SMARCAL1+/− and KU70−/−/SMARCAL1+/−
cells. The puroR gene was popped out by transient ex-
pression of cre-recombinase, resulting in the generation of
SMARCAL1Δ30/− and KU70−/−/SMARCAL1Δ30/− DT40
cells. To confirm the gene disruption by RT-PCR, the
primer set F4 and R4 was used.
Generation of human SMARCAL1−/− and
SMARCAL1−/−/LIG4−/−/− TK6 B cells
To generate a pair of TALEN expression plasmids against
the SMARCAL1 gene, we used a Golden Gate TALEN
kit and a TAL effector kit (Addgene, US) (43,44). The
TALEN target sites are shown in Supplementary Figure
S2. The gene-targeting constructs were generated from the
genomic DNA of TK6 cells by amplifying with primers
XhoI-flanked F7 and NheI-flanked R7 for the 5′-arm and
NotI-flanked F8 and HindIII-flanked R8 for the 3′-arm.
The 5′-arm PCR products were cloned into the XhoI and
NheI sites found upstream of the puroR and hygroR marker
genes of the DT-ApA/puro and DT-ApA/hygro vectors,
respectively. The 3′-arm PCR products were cloned into
the NotI and HindIII sites found downstream of the puroR
and hygroR marker genes of the DT-ApA/puro and DT-
ApA/hygro vectors, respectively. 6 g TALEN-expression
plasmids and 2 g gene-targeting vectors were transfected
into 4×106 TK6 cells using the Neon Transfection Sys-
tem (Life Technologies, US) with 3X pulse at 1350 V and
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Table 1. Panel of cell lines used in this study
Genotype Parental Cell Line Markers genes References
SMARCAL1−/− DT40 hisD, puroR *
SMARCAL1Δ30/− DT40 hisD *
KU70−/− DT40 bsrR, puroR (55)
BRCA2−/− DT40 hygroR, hisD (46)
KU70−/−/SMARCAL1Δ30/− DT40 hisD, bsrR, puroR *
SMARCAL1−/− TK6-derived TSCER2 and TSCE5 puroR, hygroR * T
LIG4−/−/− TK6-derived TSCER2 and TSCE5 puroR, neoR * C
RAD54−/− TK6-derived TSCER2 puroR, neoR * T
SMARCAL1−/−/LIG4−/−/− TK6-derived TSCE5 puroR, neoR, hygroR * T/C
DNA-PKcs−/− TK6-derived TSCE5 neoR, hisD * C
SMARCAL1−/−/DNA-PKcs−/− TK6-derived TSCE5 neoR, hisD * T/C
* = This study; T = TALEN; C = CRISPR.
with 10 ms pulse width. After electroporation, cells were re-
leased into 20 ml drug-free medium containing 10% horse
serum. Forty-eight hours later, cells were seeded into 96-well
plates with both hygromycin and puromycin antibiotics for
two weeks. The genomic DNAs of the isolated clones resis-
tant to both hygromycin and puromycin were digested with
XbaI for Southern blot analysis. A 0.6 kb probe was gener-
ated by PCR of genomic DNA using primers F9 and R9.
The loss of Smarcal1-protein expression was confirmed by
western blot analysis (Supplementary Figure S2B). The effi-
ciency of generating SMARCAL1−/−clones from wild-type
cells was 100% (3/3). Themethod for generatingLIG4−/−/−
and RAD54−/− TK6 cells is described in the Supplemen-
tal Materials and Methods. SMARCAL1−/−/LIG4−/−/−
clones were generated by disrupting the LIG4 gene in the
SMARCAL1−/− cells. Gene-targeting efficiency was 10%
(2/20).
Generation of human DNA-PKcs−/− and SMARCAL1−/−/
DNA-PKcs−/− TK6 B cells
To disrupt the DNA-PKcs gene, we designed a guide RNA
targeting the 32nd exon using the Zhang CRISPR tool (45)
and gene-targeting constructs. The CRISPR-target site is
depicted in Supplementary Figure S3E. The gene-targeting
constructs were generated using SLiCE (Seamless Ligation
Cloning Extract). The genomic DNA was amplified with
primers F19 and R19 from the DNA-PKcs-gene locus and
the PCR product was used as template DNA for amplifying
the 5′- and 3′-arms. The 5′-arm was amplified using primers
F20 and R20 and the 3′-arm was amplified using primers
F21 and R21, where each primer shared 20-base pair-end
homology with the insertion site of the vector. Both vec-
tors, DT-ApA/neo and DT-ApA/his, were linearized with
AflII and ApaI. All the fragments of the vectors and inserts
were purified using a qiaquick gel extraction kit (QIAGEN,
Netherlands). The gene-targeting constructs were generated
in a single reaction mixture containing DT-ApA/neo or
DT-ApA/his vectors, 5′- and 3′-arms, and 2×SLiCE buffer
(Invitrogen, US) and incubated for 30 min at room temper-
ature. 6 g of CRISPR and 2 g of each gene-targeting
vector were transfected into 4×106 TK6 cells using the
Neon Transfection System (Life Technologies, US). After
electroporation, cells were released into 20 ml drug-free
medium containing 10% horse serum. Forty-eight hours
later, cells were seeded into 96-well plates for selection with
both neomycin and histidinol antibiotics for twoweeks. The
gene disruption was confirmed by RT-PCR using primers
F22 and R22, and by western blot analysis with anti-DNA-
PKcs antibody (Supplementary Figure S3F). The targeting
efficiency of generating DNA-PKcs−/− clones from DNA-
PKcs+/+ cells was 90% (9/10). The targeting efficiency
of generating SMARCAL1−/−/DNA-PKcs−/− clones from
SMARCAL1−/−/DNA-PKcs+/+ cells was 100% (2/2).
Generation of SMARCAL1−/− cells reconstituted with
SMARCAL1WT, SMARCAL1R764Q or SMARCAL1Δ30
transgene
The SMARCAL1 cDNA was bought from the
Kazusa DNA research institute (Chiba, Japan). The
SMARCAL1R764Q cDNA was obtained by site-directed
mutagenesis of SMARCAL1WT (wild-type SMARCAL1)
cDNA using primers F18 and R18. The SMARCAL1Δ30
cDNA with the first 30 amino acids deleted was generated
from SMARCAL1WT cDNA by PCR using primers F10
and R10. The SMARCAL1WT, SMARCAL1R764Q and
SMARCAL1Δ30 transgenes were cloned into pMSCV-
IRES-GFP retroviral expression vector (Clontech, US).
The newly engineered retroviral expression vector was
co-transfected into human 293T cells with a helper plas-
mid (pClampho, US) to produce a viral supernatant,
which was collected after 24 hours and used to infect
the SMARCAL1−/− cells. The efficiency of infection was
assessed by quantifying the number of cells expressing
GFP using flow-cytometric analysis (LSRFortessa, BD
Biosciences, US). The cells expressing GFP were enriched
using a cell sorter (FACSAria III, BD Biosciences, US) and
seeded into 96 well plates to isolate single colonies. The
expression level of the transgenes in the SMARCAL1−/−
cells was measured by western blot (Figure 5D).
Colony-survival assay
Tomeasure sensitivity, cells were treated with camptothecin
(Topogen, Inc, US) and ICRF193 (Funakoshi, Japan) (17)
and irradiated with ionizing radiation (137Cs). Cell sensitiv-
ity to these DNA-damaging agents was evaluated by count-
ing colony formation in methylcellulose plates as described
previously (46,47).
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Figure 1. Smarcal1-deficient DT40 cells are sensitive to ICRF193 and
camptothecin. Clonogenic-cell-survival assay following exposure of the in-
dicated genotypes to DNA-damaging agents (A–D). The x-axis represents
the dose of the indicatedDNA-damaging agent on a linear scale; the y-axis
represents the survival fraction on a logarithmic scale. Error bars show the
SD of the mean for three independent assays. The P-value of (C) was cal-
culated by Student’s t-test or two-sample t-test for IR sensitivity at 2 Gy.
Cell-cycle synchronization
Cells were synchronized by centrifugal-counter-flow elutri-
ation (Hitachi Koki, Japan). The cell suspension (∼5×107
TK6 cells) was loaded at a flow rate of 15 ml/min into an
elutriation chamber rotating at 2000 rpm. Cell synchrony
was confirmed by FACS analysis (LSRFortessa, BD Bio-
sciences, US).
Immunostaining and microscopic analysis
Cells were fixed with 4% paraformaldehyde (Nacalai
Tesque, Japan) for 10 min at room temperature and perme-
abilized with 0.5% TritonX-100 (Sigma, St. Louis, US) for
20 min. To exclude S-phase cells from the count shown in
Figure 3C and D, a Click-iT EdU imaging kit (Alexa594,
Invitrogen, US) was used. Images were taken with a confo-
cal microscope (TCS SP8, Leica Microsystems, Germany)
and a BX-61 microscope (Olympus, Japan).
V(D)J-recombination assay
The V(D)J-recombination assay was performed as de-
scribed previously (48). Briefly, 4×106 TK6 cells were trans-
fected (Neon, Life Technologies, US) with 600 ng of cir-
cular pJH200 or pJH290, 5.4 g of RAG1- and 6.6 g
of RAG2-expression vector. The extrachromosomal plas-
mids were recovered from cells after 48 hours using a mod-
ified Hirt extraction method (49). The mixture of 15 l of
ElectroMAXTM DH10BTM (Life Technologies, US) com-
petent bacteria and 300 ng (range of 100–500 ng) of re-
covered plasmids were added to an electroporation cuvette
(0.1 cm gap) and incubated on ice for 10 min. The bacteria
were then electroporated at 1.8 kV, 200  and 25 uF for 2
seconds using a Gene PulserII (Bio-Rad, US). Pre-warmed
SOC media was added to the bacteria and the reaction
was incubated at 37◦C for 2 hours. The reaction was plated
on LB-agar plates containing 100 g/ml ampicillin and 10
g/ml chloramphenicol and incubated for 16–24 hours at
37◦C. The ampicillin+chloramphenicol-resistant plasmids
were isolated and subjected to ApaLI digestion to examine
the fidelity of the signal joints. Digestion of original pJH200
plasmid yields a 4.3 kb band, while that of the correct re-
combination products yields 3.5 kb + 0.8 kb bands due to
the newly generated ApaLI site. Signal-joint and coding-
joint sequences were analyzed using the sequencing primer
R17 (50).
NHEJ assay of I-Sce1-induced DSBs
A TK6-derived line that is heterozygous for point mutation
in exon4 of the thymidine-kinase gene (TK+/−) was used to
measure the frequency of NHEJ events as described previ-
ously (51,52). To measure the length of deletion in DSB-
repair products formed in wild-type and SMARCAL1−/−
cells, primers Fa and Ra were used. To measure the length
of the deletion formed in the LIG4−/−/− cells, primers Fa
and Rb were used.
Chromatin fractionation and chromatin immunoprecipitation
A Subcellular Protein Fractionation Kit from Thermo Sci-
entific (78840) was used for chromatin fractionation. Ex-
pression plasmids for aTALENand I-Sce1were transfected
into TK6 cells using the Neon Transfection System. After
20 hours, transfected cells were analyzed by western blot-
ting and ChIP. ChIP was performed as described previously
(53), with some modifications. Briefly, samples were son-
icated to generate DNA fragments of <500 bp. The anti-
body was incubated with Dynabeads Protein G for 3 hours
at 4◦C. Sheared chromatin was centrifuged at 15000 rpm
for 15 min at 4◦C. After centrifugation, supernatants were
incubated with antibody-protein G conjugates for 3 hours
at 4◦C. The conjugated beads were washed thoroughly with
IP buffer-140, IP buffer-500, IP buffer-750, LiCl/detergent
and TE. Real-time PCR was carried out as described previ-
ously (53). Sequences of primers are given in Supplemental
Table S1.
Antibodies
Anti-H2AX mouse monoclonal (1:1000, Millipore, US);
anti-TP53BP1 rabbit polyclonal (1:100, Sigma, US); alexa
fluor 488-conjugated anti-mouse IgG (1:1000, Molecu-
lar Probes); alexa fluor 488–conjugated anti-rabbit IgG
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Figure 2. Sensitivity of human SMARCAL1−/−, SMARCAL1−/−/LIG4−/−/− and SMARCAL1−/−/DNA-PKcs−/− TK6 B cells to ICRF193 and  -rays.
(A–E) Cellular sensitivity is shown as in Figure 1. Error bars show the SD of the mean for three independent assays. P-values were calculated by Student’s
t-test.
(1:1000, Molecular Probes); anti-Smarcal1 rabbit poly-
clonal (ab154226, abcam, UK); anti-XRCC4 goat poly-
clonal (C-20, Santa Cruz, US); anti-Ku70mouse polyclonal
(#GTX70270, Gene Tex, US); anti-DNA-PKcs mouse
monoclonal (ab1832, abcam, UK).
RESULTS
SMARCAL1-deficient cells are sensitive to DNA-damaging
agents
To analyze the role of Smarcal1 in the DSB-repair path-
way, we disrupted the SMARCAL1 gene and gener-
ated SMARCAL1−/− DT40 cells (Supplementary Fig-
ures S1A and S1C). Moreover, to selectively analyze the
function of the Smarcal1-RPA interaction, we generated
SMARCAL1Δ30/− DT40 mutant cells by deleting the N-
terminal region encoding the RPA-binding site of the en-
dogenous SMARCAL1 gene (9) (Supplementary Figures
S1D and S1E). To define the role played by Smarcal1 in
various DNA-repair processes, we measured cellular re-
sponses to exogenous DNA damages. SMARCAL1−/− and
SMARCAL1Δ30/− DT40 cells exhibited increased sensitiv-
ities to various DNA-damaging agents, including camp-
tothecin and ICRF193 (Figures 1A and B). The sensitiv-
ity profile of the SMARCAL1Δ30/− cells was very simi-
lar to that of the SMARCAL1−/− cells, suggesting that
the physical association of Smarcal1 with RPA is essen-
tial for its DNA-damage response (9). The elevated sen-
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Figure 3. Repair of  -ray induced DSBs at the G1 phase in TK6 cells. (A) DNA content of G1-synchronized TK6 cells. (B) Cellular sensitivity of G1-
synchronized cells to -rays, shown as in Figure 1. Error bars indicate the SD of the mean for three independent assays. P-value was calculated by Student’s
t-test. (C) Histogram representing the H2AX subnuclear foci of G1 cells after irradiation with 1 Gy -rays. The x-axis represents time after  -irradiation
(time zero); the y-axis represents the average number of H2AX foci in individual cells. The nuclei of 100 morphologically intact cells were analyzed at
each time point in individual experiments. The experiment was performed at least three times, with the averages presented with SD and P-values. Asterisks
indicate statistical significance; *P = 0.0055 and **P = 0.00020. (D) Histogram representing the 53BP1 subnuclear foci of G1 cells, as shown in (C). The
experiment was performed at least three times, with averages presented with SD and P-value. Asterisks indicate statistical significance; *p = 6.3×10−5.
sitivity to camptothecin supports the idea that Smarcal1
helps to prevent replication forks from replication col-
lapse at one-end breaks, as indicated previously (1,2,8–
10,54). NHEJ-deficient KU70−/− cells (55), but not HR-
deficient BRCA2−/−cells (46), showed a hypersensitivity
to ICRF193 (Figure 1B). We further analyzed the func-
tional relationship between Smarcal1 and Ku70 by generat-
ing KU70−/−/SMARCAL1Δ30/− double-mutant cells. The
double-mutant cells showed virtually the same ICRF193
sensitivity as did the KU70−/− single mutant (Figure 1D),
indicating that Smarcal1 is epistatic to Ku70.
To investigate the role of Smarcal1 in human cells,
we disrupted the SMARCAL1 gene in the human TK6
B cell line using a TALEN pair combined with gene-
disruption constructs (Supplementary Figures S2A and
S2B). We also generated both LIG4−/−/− (Supplementary
Figures S3A and S3B) and RAD54−/− TK6 clones (Sup-
plementary Figures S3C and S3D) as controls deficient
in NHEJ and HR, respectively. In addition, we gener-
ated DNA-PKcs−/− TK6 clones (Supplementary Figures
S3E and S3F). The TK6 cell line has been widely used
by the governments of developed countries to detect en-
vironmental mutagens due to the very stable phenotype
and karyotype of its cells (56,57). The SMARCAL1−/−cells
proliferated with kinetics (15 h per cell cycle) and plat-
ing efficiency (58%) similar to that of wild-type TK6 cells.
Like the DT40 mutants, human SMARCAL1−/− cells were
moderately but also significantly sensitive to camptothecin
(Figure 2A). Three SMARCAL1−/− clones and NHEJ-
deficient LIG4−/−/− and DNA-PKcs−/−, but not HR-
deficient RAD54−/−, were sensitive to ICRF193 (Figure
2B, Supplementary Figures S2C and S4B). Additionally,
LIG4−/−/− and SMARCAL1−/−/LIG4−/−/− cells showed
the same sensitivity to ICRF193 (Figure 2D). Likewise,
DNA-PKcs−/− and SMARCAL1−/−/DNA-PKcs−/− cells
showed the same sensitivity to ICRF193 (Supplementary
Figure S4B). We thus conclude that Smarcal1 promotes the
canonical NHEJ pathway in both DT40 and TK6 cell lines.
Human SMARCAL1−/− cells are defective for DSB repair
in the G1 phase
SMARCAL1−/− DT40 and TK6 cells were significantly ra-
diosensitive (Figures 1C and 2C and Supplementary Figure
S2C). Remarkably, SMARCAL1−/−, DNA-PKcs−/− and
SMARCAL1−/−/DNA-PKcs−/− TK6 cells showed very
similar radiosensitivity (Figure 2E and Supplementary Fig-
ure S4A). To further investigate the role of Smarcal1 in
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NHEJ, we measured sensitivity to ionizing radiation (IR)
in the G1 phase (Figure 3A and Supplementary Figure
S5A). SMARCAL1−/− as well as LIG4−/−/− cells showed
a hypersensitivity to IR (Figure 3B). As expected, the
SMARCAL1−/−/LIG4−/−/− cells showed the same hyper-
sensitivity to IR as did the LIG4−/−/− cells in the G1 phase
(Figure 3B). We then monitored DSB repair kinetics in
the G1 phase by counting the number of H2AX and
53BP1 foci over time after exposure to IR. The resolu-
tion of 53BP1 and H2AX foci was significantly delayed
in SMARCAL1−/− cells compared to wild-type cells (Fig-
ures 3C, D and Supplementary Figure S5B). These results
indicate that SMARCAL1−/− cells are deficient in DSB re-
pair in the G1 phase. We therefore conclude that Smarcal1
promotes DSB repair by NHEJ in both human and chicken
DT40 cells.
Deletion of Smarcal1 does not compromise the fidelity of
NHEJ
To address the accuracy of individualDSB-repair events, we
performed two experiments using TK6 cells, (i) the analysis
of V(D)J recombination (Figure 4) and (ii) the repair of I-
Sce1 induced DSBs by NHEJ (Figure 5).
V(D)J recombination is initiated by the Rag1 and Rag2
recombinase proteins, which introduce DSBs at the re-
combination signal (RS) (58,59) and complete recombi-
nation by collaborating with canonical NHEJ. We used
two episomal V(D)J-recombination substrates, pJH200 and
pJH290, where the recombinase generates the RS and
coding-joint products, respectively (50) (Figure 4A). We
transiently transfected expression plasmids encodingRAG1
and RAG2 along with either pJH200 or pJH290 into wild-
type and SMARCAL1−/− and LIG4−/−/− cells (Figure
4B). We then recovered the transfected substrate plasmids
from the TK6 cells, introduced the plasmids into bacte-
rial cells, and plated them on LB agar plates containing
either ampicillin or chloramphenicol. Ampicillin-resistant
colonies contained recovered pJH200 or pJH290 plasmids,
while colonies resistant to chloramphenicol contained only
rearranged pJH200 or pJH290 plasmids. Thus, the fre-
quency of rearrangement can be calculated as the gain
of chloramphenicol-resistant (camR) colonies relative to
the total number of ampicillin-resistant (ampR) colonies.
The signal-joint ends are precisely ligated, whereas the
coding ends are joined in a process that can involve nu-
cleotide loss or gain in addition to simple ligation (60). We
failed to recover any rearranged signal-joint products from
LIG4−/−/− cells, which agrees with the essential role for
DNA Ligase4 in signal-joint formation (61,62). The effi-
ciency of recombination in the signal-joint and coding-joint
plasmids was decreased 2.3 and 2.4 times, respectively, in
SMARCAL1−/− cells, when compared with wild-type cells
(Figure 4C). The nucleotide sequence analysis of signal-
joint products indicated that only a single product among
the 29-analyzed sequences contained one nucleotide dele-
tion in SMARCAL1−/− cells (data not shown). Analysis
of coding joints, on the other hand, showed more frequent
deletion events in SMARCAL1−/− as well as in wild-type
cells, with the extent and frequency of deletion being com-
parable between the two genotypes (Supplemental Table
S2). Thus, the loss of Smarcal1 reduces the efficiency of
canonical NHEJ without compromising its fidelity.
We next examined individual DSB-repair events in the
human TK6 cell line, which is heterozygous (+/-) for the
thymidine kinase (TK) gene and contains an I-Sce1 endonu-
clease recognition site in the fourth intron of the intact
TK allele (51) (Figure 5A). If the repair of I-Sce1-induced
DSBs causes the deletion of more than 100 nucleotides
downstream from the I-Sce1 site, the deletion would in-
activate the fifth exon, leading to the formation of TK−/−
cells, which cells are able to form colonies in the negative-
selection media containing trifluorothymidine (TFT) (Fig-
ure 5A). We found that the number of TFT-resistant clones
was reduced by 8 and 5 times in the LIG4−/−/− and
SMARCAL1−/− cells, respectively, when compared with
wild-type cells (Figure 5B). To analyze deletion range and
pattern, we isolated at least 50 individual TFT-resistant
clones from each genotype. Genomic PCR amplification
over the I-Sce1 site indicated that deletion was two times
shorter in the SMARCAL1−/− cells and approximately 0.5
times longer in LIG4−/−/− cells, compared with wild-type
cells (Figure 5C and Supplementary Figure S6). In sum-
mary, we conclude that Smrcal1 promotes NHEJ without
affecting its accuracy.
The RPA-binding domain and the ATPase domains are both
required for the promotion of NHEJ by Smarcal1
The phenotypic analysis of SMARCAL1Δ30/− DT40 cells
indicated that the RPA-binding site is essential for Smar-
cal1 to function in NHEJ. To confirm the relevance
of this finding to human cells, we reconstituted the
SMARCAL1−/− TK6 cells with the RPA-binding-site-
deficient (SMARCAL1Δ30) transgene as well as the wild-
type (SMARCAL1WT) transgene. The expression level of
the Smarcal1 protein in the reconstituted cells was simi-
lar to that in the wild-type cells (Figure 5D, lower panel).
As expected, reconstitution of SMARCAL1−/− cells with
the SMARCAL1WT transgene normalized the NHEJ-
mediated repair of I-Sce1-induced DSBs (Figure 5E). The
SMARCAL1Δ30 transgene failed to normalize NHEJ, in-
dicating that the RPA-binding site plays a role in pro-
moting NHEJ by Smarcal1 in human cells. Moreover,
SMARCAL1−/− cells and SMARCAL1Δ30 transgene ex-
hibited similar sensitivity toDNA-damaging agent (Supple-
mentary Figure S4C), demonstrating that the RPA-binding
site is critical for Smarcal1 DNA repair function. Next, to
investigate the role of annealing helicase activity, we in-
troduced a point mutation (Arginine 764 to Glutamine,
R764Q) into the ATPase domain of the SMARCAL1WT
transgene, which mutation has no detectable annealing he-
licase activity (2) and causes a severe form of Schimke
immuno-osseous dysplasia (SIOD) (4). Reconstitution with
the resulting SMARCAL1R764Q transgene did not restore
the repair of I-Sce1-induced DSBs (Figure 5D and E). We
therefore conclude that the annealing helicase activity as
well as the physical association of Smarcal1 with RPA is re-
quired for the promotion of NHEJ by Smarcal1. One possi-
ble scenario is that Smarcal1 promotesNHEJ by interacting
with unwoundDSB ends associated withRPA and facilitate
their annealing.
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Figure 4. The loss of Smarcal1 reduces the efficiency of V(D)J recombination without compromising its fidelity. (A) The structure of two episomal V(D)J-
recombination substrates, pJH200 and pJH290, and their recombination products. Open triangles and closed boxes represent recombination signals (RSs)
and V(D)J-coding sequences, respectively. CamR = chloramphenicol-resistance gene; P = promoter. (B) Schematic representation of the experimental
method for the V(D)J-recombination assay. Frequency of recombination was calculated by dividing the number of rearranged products (the number of
camR colonies) by the number of recovered plasmids (the number of ampicillin-resistant [ampR] colonies). (C) Recombination frequency of TK6 cells
carrying the indicated genotypes. Data shown are the means of more than three experiments. Error bars indicate SD of more than three independent
experiments. P-value was calculated by Student’s t-test. The total number of ampicillin- and chloramphenicol-resistant colonies is shown in the right
panel. Supplemental Table S2 shows the nucleotide sequences of coding joints associated with deletion events.
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Figure 5. The fidelity of end-joining in SMARCAL1mutant cells. (A) Schematic diagram showing DSB-repair events that repair I-Sce1-induced DSBs in
the endogenous thymidine kinase (TK) locus. TK+/− cells carry an I-Sce1 site in intronic sequences of the wild-type TK allele and a mutation in exon4 of
the mutant TK allele. DSB repair associated with deletion in exon5 coding sequences would yield TK−/− clones from TK+/− cells. The number of TK−/−
clones was measured by counting the number of trifluorothymidine (TFT)-resistant colonies. (B) Histogram representing the frequency of DSB-repair
events (y-axis) in the indicated genotypes (x-axis). Error bars indicate SD of more than three independent experiments. P-value was calculated by Student’s
t-test. (C) Box plot representing the length of nucleotide deletion (y-axis) in the indicated genotypes (x-axis). PCR was performed from genomic DNA
isolated from at least 50 TFT-resistant clones of each genotype, as shown in Supplementary Figure S6. (D) Schematic representation of the structure of
wild-type, R764Q and30 Smarcal1 proteins. SMARCAL1−/− TK6 cells were reconstituted with SMARCAL1WT, SMARCAL1Δ30 or SMARCAL1R764Q
transgene. Western blot analysis for the expression of individual transgenes in SMARCAL1−/− cells. -actin was used as a loading control. (E) Histogram
representing the frequency of TFT-resistant colonies (y-axis) in the indicated genotypes (x-axis). Error bars indicate SD of more than three independent
experiments.
Annealing of double-strand DNA by purified Smarcal1
(2) suggests that Smarcal1 facilitates NHEJ by stabiliz-
ing the physical interaction between Ku70/Ku80/DNA-
PKcs proteins and DSB ends, thereby activating DNA-
PKcs. To test this hypothesis, we analyzed the phospho-
rylation status of threonine 2609 (63,64) after treatment
with the topoisomerase 2 inhibitors ICRF193 (Supplemen-
tary Figures S7A and S7B) and etoposide (Supplemen-
tary Figure S7C). Strikingly, the phosphorylated threo-
nine 2609 was detectable only in the wild-type and not
in the SMARCAL1−/− cells (Supplementary Figures S7B
and S7C). The compromised phosphorylation of DNA-
PKcs may account for the decreased efficiency of NHEJ,
as the substitution of the threonine 2609 site to alanine
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causes radio-sensitivity and reduced V(D)J recombination
efficiency, which sensitivity is less prominent than that of
DNA-PKcs null-mutant cells (64). We propose that Smar-
cal1 promotes NHEJ, presumably at an initial step, by facil-
itating the physical association of Ku70/Ku80/DNA-PKcs
proteins and DSB ends.
Smarcal1 is required for the recruitment of XRCC4 to DNA-
damage sites
To investigate early and late steps of NHEJ, we moni-
tored the dynamics of Ku70 and XRCC4 proteins, respec-
tively, in the chromatin-bound fraction, following exposure
of cells to ICRF193 for one hour (Figure 6). This expo-
sure did not affect the purification of the chromatin-bound
or the nuclear-soluble fractions (Figure 6A). Exposure to
ICRF193 caused a marked increase in the amounts of both
Ku70 and XRCC4 in the chromatin-bound fraction of wild-
type cells. In marked contrast, accumulations of Ku70 and
XRCC4 in the SMARCAL1−/− as well as DNA-PKcs−/−
cells were, significantly smaller compared with wild-type
cells (Figure 6B and C).
To validate the significant reduction in the accumulation
of XRCC4 near DSB sites, we conducted chromatin im-
munoprecipitation (ChIP) following transient transfection
of empty vector and expression vectors encoding the I-Sce1
restriction enzyme and a TALEN towards the p53 locus
(Figure 6D). XRCC4 is supposed to accumulate at theTK-I
or p53-I sites, which are adjacent to the DSB sites, but not
at the TK-II or p53-II sites, which are distant from the DSB
sites (Figure 6D). Transient expression of I-Sce1 or TALEN
caused the accumulation of XRCC4 near the DSB sites in
wild-type cells, whereas the extent of the accumulation was
significantly reduced in SMARCAL1−/− cells (Figure 6E
and Supplementary Figure S7D). We checked the overall
expression levels of XRCC4 (Supplementary Figure S7B)
to confirm that the deletion of Smarcal1 did not alter the
level of protein expression. Thus, Smarcal1 is required for
recruitment of XRCC4 to DSB sites.
Like reduced accumulation of Ku70 in the chromatin
fraction (Figures 6B and C), the amounts of Ku70 and
DNA-PKcs near the I-Sce1 site were approximately 30%
smaller in SMARCAL1−/− cells in comparison with wild-
type cells (Figures 6F and G). In summary, Smarcal1 may
promote annealing of DSB ends, which stabilizes complex
formation of Ku/DNA-PKcs at DSB sites and fully ac-
tivates DNA-PKcs. The activation may enhance the re-
cruitment of XRCC4 for the completion of DSB repair by
canonical NHEJ.
DISCUSSION
We herein show that Smarcal1 significantly contributes to
canonical NHEJ. Although the role of Smarcal1 during
DNA replication has been well established (1,3,8–10,65), it
has remained unclear whether Smarcal1 plays a role outside
the S phase. We here reveal that Smarcal1 contributes to
DSB repair by NHEJ during the G1 phase. The role played
by Smarcal1 in NHEJ is demonstrated by six points, as fol-
lows. First, the loss of Smarcal1 increases cellular sensitiv-
ity to ICRF193, which induces DSBs repair only by NHEJ
and not by HR (17) (Figures 1B and 2B). Second, null-
mutation of KU70 is epistatic to SMARCAL1Δ30 mutation
in DT40 cells (Figure 1D) and null-mutation of LIG4 is
epistatic to SMARCAL1 null-mutation in TK6 cells (Fig-
ure 2D), in terms of cellular tolerance to ICRF193. Third,
the loss of Smarcal1 significantly reduces the efficiency of
DSB repair in the G1 phase in TK6 cells (Figure 3). Fourth,
SMARCAL1 null-mutation in TK6 cells significantly com-
promises V(D)J recombination (Figure 4) as well as I-Sce1-
induced DSB repair by NHEJ (Figure 5). Fifth, SMAR-
CAL1 null-mutation impairs the phosphorylation of DNA-
PKcs at threonine 2609 (Supplementary Figures S7B and
S7C). Lastly, SMARCAL1 null-mutation diminishes the ac-
cumulation of Ku70, DNA-PKcs and XRCC4 at DNA-
damage-induced DSB sites (Figure 6). We therefore con-
clude that Smarcal1 plays a role in NHEJ.
The molecular mechanisms underlying the severe lym-
phocytopenia of SIOD patients remain unclear (4,40,41).
The lymphocytopenia might result primarily from a severe
defect in V(D)J recombination due to the reduced efficiency
ofNHEJ, according to the following studies. The analysis of
V(D)J recombination in peripheral T lymphocytes indicates
that the size of the T-cell-antigenic receptor (TCR) reper-
toire is extremely small in SIODpatients (40).Moreover, the
peripheral T lymphocytes of SIOD patients have severely
low copy number of episomal circular DNA generated as
a consequence of V(D)J recombination and contain signal
joints of the T cell receptor genes (40,41). These observa-
tions support the following scenario. A moderate defect in
NHEJ can cause a very strong decrease in the efficiency
of T-cell development in patients, since it requires produc-
tive D-J- and V-D-recombination events in both TCR and
TCR chain genes in individual thymocytes. The reduced
T-cell production by the thymusmay be compensated by en-
hanced proliferation of newly generated peripheral T lym-
phocytes (66) in SIOD patients, leading to the quick di-
lution of episomal circular DNA in individual peripheral
T lymphocytes. This enhanced proliferation could cause
a strong replication stress in SIOD patients, due to their
attenuated stabilization of replication forks. In summary,
we propose that the severe lymphocytopenia of SIOD pa-
tients (4,40,41) is attributable to the significantly reduced
efficiency of V(D)J recombination, together with attenuated
stabilization of replication forks.
A prominent question is, how does Smarcal1 facilitate
the promotion of NHEJ? We have shown that both the
loss of the RPA-binding site and the inactivation of AT-
Pase activity in Smarcal1 completely abolished the promo-
tion of NHEJ by Smarcal1 (Figure 5E). Thus, Smarcal1
plays a role in NHEJ by physically interacting with RPA
on unwound DSB ends and then facilitating their anneal-
ing. The existence of unwound single-stranded sequences
at the DSB sites is supported by the presence of RPA foci
in the  -ray irradiated G1 phase cells (67). The anneal-
ing by Smarcal1 may stabilize the interaction of DSB sites
withDNA-PKcs/Ku70/Ku80, since Ku70/Ku80 associates
with duplex DSB ends more stably than with DSBs carry-
ing single-strand tails (21–24). The stabilization of DNA-
PKcs/Ku70/Ku80 at DSB sites by Smarcal1 is verified by
data shown in Figure 6. The following data suggest the
important role of Smarcal1 in the functioning of DNA-
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Figure 6. The loss of Smarcal1 results in compromised accumulation of Ku70, DNA-PKcs and XRCC4 at DSB sites. (A) Western blot data showing
the validation of fractionation of the cytoplasmic (Cyto), nuclear soluble (NS) and chromatin-bound (CB) fractions isolated from the whole-cell extract
(WCE). (B) Western blot data show the accumulation of XRCC4 (upper panel) and Ku70 (lower panel) in the chromatin-bound fraction after one-hour
exposure of cells to ICRF193. (C) Histogram showing the quantification of XRCC4 and Ku70 in (B). The y-axis represents the amount of the chromatin-
bound fraction relative to the total amount of the chromatin-bound fraction plus the nuclear soluble fraction. (D) Downward arrows represent the I-Sce1-
(upper) and the TALEN- (lower) cutting sites in the TK and p53 genes, respectively. Pairs of horizontal opposing arrows indicate the sets of primers for
quantitative real-time PCR. (E) Histograms represent the accumulation of XRCC4 near the I-Sce1-induced DSB in the TK locus (upper panel) and near
the TALEN-induced DSB at the p53 locus (lower panel). (F) Histogram represents the accumulation of Ku70 near the I-Sce1-induced DSB in the TK
locus. (G) Histogram represents the accumulation of DNA-PKcs near the I-Sce1-induced DSB in the TK locus.
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PKcs. DNA-PKcs/Ku70/Ku80 also interacts with Smar-
cal1 in vivo (68,69). We here show that DNA-PKcs−/− and
SMARCAL1−/− have an epistatic relationship in cellular
tolerance to IR (Figure 2E). We also show that the loss
of Smarcal1 inhibits the phosphorylation of DNA-PKcs
at threonine 2609 following exposure of cells to the topoi-
somerase 2 inhibitors (Supplementary Figure S7). These
observations suggest that Smarcal1 may be required for
DNA-PKcs/Ku70/Ku80 to function appropriately.We also
show that the loss of Smarcal1 reduces the recruitment of
XRCC4 to DSB sites by several times (Figure 6). Previ-
ous studies indicate that DNA-PKcs is necessary for the
stabilization of recruited XRCC4 (70,71), which is consis-
tent with our data (Figure 6B). Thus, the effect of Smar-
cal1 on the recruitment of XRCC4 might be mediated by
DNA-PKcs/Ku70/Ku80. We therefore propose that Smar-
cal1 maintains duplex DNA status at DSB ends by inter-
acting with unwound single-strand DNA associated with
RPA and facilitating their annealing. This annealing then
stabilizes DNA-PKcs/Ku70/Ku80 at duplex DNA termini,
which is essential for the proper accumulation and stabiliza-
tion ofXRCC4 atDNAdamage sites. Future studies should
clarify the molecular mechanism.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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